An interventional study of Riboflavin and Antibotice.g vigamox ED Antifungal e.g Dflucan in Infectoius Keratitis, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.
Sponsored by Sohag University · Not applicable, Interventional, and Treatment
The primary aim of this study is to investigate the efficiency of PACK_ CXL in treatment of infectious keratitis and analyze postoperative outcomes.
108 studies on the registry are indexed under Keratitis; 19 are open to participants now.
This study's planned enrollment of 60 is above the median of 40 across 70 interventional studies indexed under Keratitis.
Browse Keratitis studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
will include 20 eyes of 20 patients with infectious keratitis who will receive antimicrobial therapy.
Drug: Antibotice.g vigamox ED Antifungal e.g Dflucan
will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated cross-linking Protocol-1 (9 mW/cm2 for 10 minutes to achieve 5.4 J/cm2) followed by antimicrobial therapy
Drug: Riboflavin · Drug: Antibotice.g vigamox ED Antifungal e.g Dflucan · Device: pack cross linking
will include 20 eyes of 20 patients with infectious keratitis who will undergo PACK accelerated crosslinking Protocol-2 (18 mW/cm2 for 7 minutes to achieve 7.2 J/cm2) followed by antimicrobial therapy
Drug: Riboflavin · Drug: Antibotice.g vigamox ED Antifungal e.g Dflucan · Device: pack cross linking
topical application of riboflavin followed by cross linking
topical application of antimicropial therapy
TOPICAL application of cross linking after application of Riboflavin TO TREAT INFECTIOUS KERATITIS
corneal THICKNESS
decrease corneal THICKNESS USING ANTERIOR SEGMENT OPTICAL COHERENT TOPOGRAPHY
Time frame: within 60 days
Start is estimated for Jun 2023; primary completion for Apr 2024, 10 months later.
Of 12 interventional studies with no phase under Keratitis, half reached primary completion within 20 months of starting (the median); a quarter within 5 and three quarters within 24. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin